Efficacy and Safety of Lumateperone and Other Atypical Antipsychotics Approved as Adjunctive Treatment for Major Depressive Disorder in the United States: A Network Meta-Analysis - PubMed
5 hours ago
- #Network Meta-Analysis
- #Major Depressive Disorder
- #Lumateperone
- The study is a network meta-analysis comparing the efficacy and safety of lumateperone with other atypical antipsychotics (aripiprazole, brexpiprazole, cariprazine, quetiapine XR) as adjunctive treatments for major depressive disorder (MDD).
- All atypical antipsychotics showed greater efficacy than placebo in reducing MADRS scores, with lumateperone 42 mg/day showing the highest mean difference (-4.70). Lumateperone ranked highest in efficacy across endpoints.
- Lumateperone was the only treatment with no weight gain relative to placebo and ranked favorably for weight-related safety. It performed better than average for akathisia risk but below average for somnolence risk.
- The analysis included 10 registrational RCTs from US product labeling, using a Bayesian fixed-effect approach and SUCRA for ranking. Efficacy outcomes included MADRS change, response, remission, and CGI-S change.
- The authors note conflicts of interest, including employment by Johnson & Johnson and Analysis Group, which funded the study. Ethical approval was not required as it was a secondary analysis.